High-dose Spinraza inches closer to EU approval despite FDA setback
A CHMP panel has recommended the high-dose version’s approval, countering an FDA rejection for the drug in recent months.
Neurology
Modulight secures $12m to shine precise light on neurological diseases
J&J’s Caplyta wins MDD approval to extend revenue horizon
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
FDA delays approval decision for Sanofi’s MS treatment tolebrutinib
Reunion Neuroscience expands Series A to $133m after positive trial milestones
Novartis returns to alpha-synuclein with $2.2bn Arrowhead deal
Eisai’s Leqembi unlocks at-home dosing with FDA autoinjector approval
